Subcutaneous interleukin-4 for relapsed non-Hodgkin's lymphoma: A phase II trial in the North Central Cancer Treatment Group, NCCTG 91-78-51.

被引：0
|
作者：
Kurtz, D. M. [1 ]
Tschetter, L. K. [1 ]
Allred, J. B. [1 ]
Geyer, S. M. [1 ]
Kurtin, P. J. [1 ]
Putnam, W. D. [1 ]
Rowland, K. M. [1 ]
Wiesenfeld, M. [1 ]
Soori, G. S. [1 ]
Tenglin, R. C. [1 ]
Bernath, A. M. [1 ]
Witzig, T. E. [1 ]
机构：
[1] Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA
来源：
JOURNAL OF INVESTIGATIVE MEDICINE | 2007年 / 55卷 / 02期
关键词：
D O I：
10.1097/00042871-200703010-00088
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
81
引用
收藏
页码：S362 / S362
页数：1
相关论文
共 50 条
  • [1] Subcutaneous interleukin-4 (IL-4) for relapsed and resistant non-Hodgkin lymphoma: A phase II trial in the North Central Cancer Treatment Group, NCCTG 91-78-51
    Kurtz, David M.
    Tschetter, Loren K.
    Allred, Jacob B.
    Geyer, Susan M.
    Kurtin, Paul J.
    Putnam, Wesley D.
    Rowland, Kendrith M., Jr.
    Wiesenfeld, Martin
    Soori, Gamini S.
    Tenglin, Richard C.
    Bernath, Albert M.
    Witzig, Thomas E.
    LEUKEMIA & LYMPHOMA, 2007, 48 (07) : 1290 - 1298
  • [2] Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: A phase II trial in the North Central Cancer Treatment Group
    Witzig, Thomas E.
    Geyer, Susan M.
    Kurtin, Paul J.
    Colgan, Joseph P.
    Inwards, David J.
    Micallef, Ivana N. M.
    LaPlant, Betsy R.
    Michalak, John C.
    Salim, Muhammad
    Dalton, Robert J.
    Moore, Dennis F., Jr.
    Reeder, Craig B.
    LEUKEMIA & LYMPHOMA, 2008, 49 (06) : 1074 - 1080
  • [3] Phase II evaluation of interleukin-4 in patients with non-Hodgkin's lymphoma: a Southwest Oncology Group Trial
    Taylor, CW
    LeBlanc, M
    Fisher, RI
    Moore, DF
    Roach, RW
    Elias, L
    Miller, TP
    ANTI-CANCER DRUGS, 2000, 11 (09) : 695 - 700
  • [4] Salvage chemotherapy with rituximab DHAP (RDHAP) for relapsed non-Hodgkin lymphoma (NHL): A phase II trial in the North Central Cancer Treatment Group.
    Witzig, T. E.
    Geyer, S. M.
    Kurtin, P. J.
    Colgan, J. P.
    Inwards, D. J.
    Micallef, I. N.
    Michalak, J. C.
    Salim, M.
    Nikcevich, D. A.
    Dakhil, S. R.
    Fitch, T. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 440S - 440S
  • [5] Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease
    Younes, A
    Pro, B
    Robertson, MJ
    Flinn, IW
    Romaguera, JE
    Hagemeister, F
    Dang, NH
    Fiumara, P
    Loyer, EM
    Cabanillas, FF
    McLaughlin, PW
    Rodriguez, MA
    Samaniego, F
    CLINICAL CANCER RESEARCH, 2004, 10 (16) : 5432 - 5438
  • [6] Rituximab therapy for patients with newly diagnosed, asymptomatic advanced-stage follicular grade I non-Hodgkin's lymphoma (NHL): A phase II trial in the North Central Cancer Treatment Group (NCCTG).
    Witzig, TE
    Vukov, AM
    Habermann, TM
    Geyer, S
    Friedenberg, WR
    White, WL
    Salim, M
    Flynn, PJ
    Fitch, TR
    Morton, RF
    BLOOD, 2002, 100 (11) : 361A - 361A
  • [7] Phase I/II Trial of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
    Kallam, Avyakta
    Meza, Jane
    Bierman, Philip
    Lunning, Matthew A.
    Bociek, R. Gregory
    Armitage, James Olen
    Vose, Julie M.
    BLOOD, 2017, 130
  • [8] Phase I/II trial of clofarabine in refractory and/or relapsed non-Hodgkin's lymphoma (NHL)
    Nabhan, C.
    Fried, W.
    Galvez, A.
    Venugopal, P.
    Bitran, J. D.
    ANNALS OF ONCOLOGY, 2008, 19 : 243 - 243
  • [9] Phase I/II trial of clofarabine in refractory and/or relapsed non-hodgkin's lymphoma (NHL)
    Nabhan, C.
    Fried, W.
    Galvez, A.
    Venugopal, P.
    Gozun, P.
    Bitran, J. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] A North Central Cancer Treatment Group phase II trial of topotecan in relapsed gliomas
    Burch, PA
    Bernath, AM
    Cascino, TL
    Scheithauer, BW
    Novotny, P
    Nair, S
    Buckner, JC
    Pfeifle, DM
    Kugler, JW
    Tschetter, LK
    INVESTIGATIONAL NEW DRUGS, 2000, 18 (03) : 275 - 280
12345